Dimethyl Sulfoxide

Dimethyl Sulfoxide

SCHEMBL1665533

C[S+](C)[O-].C[S+](C)[O-].ClCCl

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MAP2K1MAP2K2

The experimentally established mechanism targets of Dimethyl Sulfoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024132895-A1 MICROBIOCIDAL DIHYDROOXADIAZINYL PYRIDAZINONE COMPOUNDS SYNGENTA CROP PROTECTION AG (CH) 2024-06-27 WO disclosed
WO-2024132901-A1 MICROBIOCIDAL PYRIDAZINE DIHYDROOXADIAZINE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-06-27 WO disclosed
EP-4146345-A2 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF Teon Therapeutics, Inc. (US) 2023-03-15 EP disclosed
EP-4136091-A1 FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2023-02-22 EP disclosed
CN-112300247-B Teixobactin analogue and application thereof 广东东阳光药业有限公司 2022-12-27 CN disclosed
WO-2022266426-A1 6-(HETEROCYCLOALKYL-OXY)-QUINAZOLINE DERIVATIVES AND USES THEREOF BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-12-22 WO disclosed
WO-2021226206-A2 CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF TEON THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed
WO-2021211930-A1 FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2021-10-21 WO disclosed
WO-2021211938-A1 SOLID FORMS OF INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2021-10-21 WO disclosed
CN-112300247-A Teixobactin analogue and application thereof 广东东阳光药业有限公司 2021-02-02 CN disclosed
WO-2007145957-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2007-12-21 WO disclosed
WO-2007128815-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2007-11-15 WO disclosed
WO-2007108754-A1 CRYSTALLINE FORMS OF N- {2-TERT -BUTYL -1- [ (4,4- DIF LUOROCYCLOHEXYL) METHYL] -LH-BENZIMIDAZOL-5- YL}ETHANESULFONAMIDE SALTS ASTRAZENECA AB (SE) 2007-09-27 WO disclosed
EP-1828153-A1 N-(2-AMINOPHENYL)-4-(5-((ETHYLAMINO)METHYL)-1,3-THIAZOL-2-YL)BENZAMIDE AND N-(2-AMINOPHENYL)-4-(5-((ISOPROPYLAMINO)METHYL)-1,3-THIAZOL-2-YL)BENZAMIDE AS HDAC INHIBITORS AstraZeneca AB (SE) 2007-09-05 EP disclosed
WO-2007054693-A1 USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS HELPERBY THERAPEUTICS LIMITED (GB) 2007-05-18 WO disclosed
EP-1699766-A1 AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2006-09-13 EP disclosed
WO-2006064246-A1 N- (2-AMINOPHENYL) -4- (5- ((ETHYLAMINO) METHYL) 1,3-THIAZOL-2-YL) BENZAMIDE AND N- (2-AMINOPHEYNL) -4- (5- ((ISOPROPYLAMINO) METHYL) -1,3-THIAZOL-2-YL) BENZAMIDE AS HDAC INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed
EP-1660531-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-05-31 EP disclosed
WO-2005061465-A1 AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTO KINE INHIBITORS ASTRAZENECA AB (SE) 2005-07-07 WO disclosed
WO-2005012347-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2005-02-10 WO disclosed